These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 38621633)
1. Kidney Energetics and Cyst Burden in Autosomal Dominant Polycystic Kidney Disease: A Pilot Study. Bjornstad P; Richard G; Choi YJ; Nowak KL; Steele C; Chonchol MB; Nadeau KJ; Vigers T; Pyle L; Tommerdahl K; van Raalte DH; Hilkin A; Driscoll L; Birznieks C; Hopp K; Wang W; Edelstein C; Nelson RG; Gregory AV; Kline TL; Blondin D; Gitomer B Am J Kidney Dis; 2024 Sep; 84(3):286-297.e1. PubMed ID: 38621633 [TBL] [Abstract][Full Text] [Related]
2. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease. D'Agnolo HMA; Casteleijn NF; Gevers TJG; de Fijter H; van Gastel MDA; Messchendorp AL; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JFM; Zietse R; Gansevoort RT; Drenth JPH Am J Nephrol; 2017; 46(3):239-248. PubMed ID: 28881341 [TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW; Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837 [TBL] [Abstract][Full Text] [Related]
4. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease. Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110 [TBL] [Abstract][Full Text] [Related]
5. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis. Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419 [TBL] [Abstract][Full Text] [Related]
6. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease. Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C; J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065 [TBL] [Abstract][Full Text] [Related]
7. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ; Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709 [TBL] [Abstract][Full Text] [Related]
8. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535 [TBL] [Abstract][Full Text] [Related]
9. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP; Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554 [TBL] [Abstract][Full Text] [Related]
10. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease. Coban M; Inci A Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395 [TBL] [Abstract][Full Text] [Related]
11. Association of kidney and cysts dimensions with anthropometric and biochemical parameters in patients with ADPKD. Pietrzak-Nowacka M; Safranow K; Palacz J; Gołembiewska E; Marchelek-Myśliwiec M; Ciechanowski K Ren Fail; 2015 Jun; 37(5):798-803. PubMed ID: 25869055 [TBL] [Abstract][Full Text] [Related]
12. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB; Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310 [TBL] [Abstract][Full Text] [Related]
13. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171 [TBL] [Abstract][Full Text] [Related]
14. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Bae KT; Zhou W; Shen C; Landsittel DP; Wu Z; Tao C; Chapman AB; Torres VE; Yu ASL; Mrug M; Bennett WM; Harris PC; Clin J Am Soc Nephrol; 2019 Jun; 14(6):823-833. PubMed ID: 31088850 [TBL] [Abstract][Full Text] [Related]
15. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). Nakajima A; Lu Y; Kawano H; Horie S; Muto S Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206 [TBL] [Abstract][Full Text] [Related]
17. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease. Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT; Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028 [TBL] [Abstract][Full Text] [Related]
18. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G; PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521 [TBL] [Abstract][Full Text] [Related]